Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Mohamad E AllafSe-Eun KimViraj MasterDavid F McDermottLauren C HarshmanSuzanne M ColeCharles G DrakeSabina SignorettiMahmut AkgulNicholas BaniakElsa Li-NingMatthew B PalmerHamid EmamekhooNabil AdraHristos KaimakliotisYasser GedPhillip M PierorazioE Jason AbelMehmet A BilenKenneth OganHelen H MoonKrishna A RamaswamyEric A SingerTina M MayerJay LohreyVitaly MargulisJessie GillsScott E DelacroixMark J WaplesAndrew C JamesPeng WangToni ChoueiriM Dror MichaelsonAnil KapoorDaniel Y HengBrian ShuchBradley C LeibovichPrimo N LaraJudith ManolaDeborah MaskensDena BattleRobert UzzoGennady BratslavskyNaomi B HaasMichael A CarducciPublished in: The Lancet. Oncology (2024)
US National Institutes of Health National Cancer Institute and Bristol Myers Squibb.
Keyphrases
- renal cell carcinoma
- open label
- double blind
- placebo controlled
- clinical trial
- public health
- healthcare
- robot assisted
- mental health
- patients undergoing
- cardiac surgery
- quality improvement
- study protocol
- health information
- editorial comment
- health promotion
- acute kidney injury
- human health
- minimally invasive
- social media